Welcome to our dedicated page for Larimar Therapeutics SEC filings (Ticker: LRMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Larimar Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing nomlabofusp for Friedreich’s ataxia and other potential rare-disease programs using an intracellular delivery platform. Its 8-K reports disclose operating and financial results, FDA-related program updates, corporate presentations, material events and risk language around product development, regulatory review, capital needs and clinical execution.
The company’s SEC record also includes capital-structure and governance disclosures. Filings describe registered common stock on the Nasdaq Global Market, equity financing activity, an exchange involving Series A convertible preferred stock, preferred-stock conversion limitations, shareholder voting matters, executive compensation and board governance through proxy materials.
Larimar Therapeutics, Inc. provides a detailed update on its nomlabofusp program for Friedreich’s ataxia, highlighting regulatory progress, clinical data and funding. Nomlabofusp holds FDA Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations, plus PRIME and other expedited designations in Europe and the UK.
The company plans a Biologics License Application seeking accelerated approval in June 2026, supported by an open-label study and a planned global Phase 3 trial using Upright Stability Score and mFARS as primary endpoints. Open-label data show sustained, dose‑dependent increases in skin frataxin, with 100% of 10 evaluated participants above 50% of healthy volunteer levels at 180 days.
Clinical outcomes over one year numerically improved across multiple measures versus a matched FACOMS natural history cohort. Around 8,000 doses have been administered; most adverse events were injection‑site reactions, though 7 of 39 open‑label participants experienced anaphylaxis that resolved with standard treatment. Pro forma cash and investments of $244.5 million as of December 31, 2025 provide an estimated runway into the second quarter of 2027.
Larimar Therapeutics’ major shareholder group Deerfield has updated its ownership following a February 2026 stock offering. Deerfield-affiliated funds bought additional common shares at $5.00 per share in an underwritten offering on February 27, 2026, using available cash.
After these purchases, Deerfield entities report beneficial ownership of 35,667,474 shares of Larimar common stock, or 34.41% of the company’s 103,590,392 shares outstanding, including those issued in the February 2026 offering. Individual Deerfield funds now hold between roughly 5.99% and 10.25% of the outstanding shares.
Larimar Therapeutics, Inc. reported that investment funds managed by Deerfield entities associated with James E. Flynn made significant open-market purchases of its common stock. On February 27, 2026, Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Healthcare Innovations Fund, L.P., and Deerfield Partners, L.P. collectively bought 5,000,000 shares of Larimar common stock at $5.00 per share in indirect transactions. Following these purchases, each fund reported updated indirect holdings in Larimar, while the reporting persons collectively disclaimed beneficial ownership beyond any indirect pecuniary interest described in the footnotes.
Larimar Therapeutics, Inc. director Thomas Edward Hamilton bought 100,000 shares of common stock in an underwritten offering at $5.00 per share, which closed on February 27, 2026. Following this open-market purchase, he directly owns 664,798 shares and indirectly holds 159,433 shares through Post Edison, LLC.
Larimar Therapeutics director Frank E. Thomas bought common stock in the company through its underwritten offering. On February 27, 2026, he purchased 5,000 shares of Larimar Therapeutics common stock at $5.00 per share in an open-market style purchase tied to the offering. After this transaction, he directly owned 7,000 shares of common stock.
Larimar Therapeutics director Jeffrey W. Sherman bought 5,000 shares of the company’s common stock at $5.00 per share in an underwritten offering that closed on February 27, 2026. The transaction is reported as a direct, open-market style purchase on a Form 4 insider filing.
Larimar Therapeutics, Inc. entered into an underwriting agreement to sell 20,000,000 shares of common stock at a public offering price of $5.00 per share. The underwriters also received a 30-day option to buy up to 3,000,000 additional shares, which was fully exercised on February 26, 2026.
After underwriting discounts, commissions and estimated expenses, the Company expects net proceeds of approximately $107.6 million from this offering. All shares are being sold by the Company under an existing Form S-3 shelf registration, and the offering is expected to close on February 27, 2026, subject to customary closing conditions.
Larimar Therapeutics is offering 20,000,000 shares of its common stock at a public offering price of $5.00 per share. The offering includes an underwriter option to purchase up to an additional 3,000,000 shares. Delivery of the shares is expected on or about February 27, 2026.
The cover page shows underwriting discounts of $0.30 per share and proceeds to the company before expenses of $94,000,000. The offering is being made from a shelf registration on Form S-3 and assumes no exercise of outstanding options; management retains broad discretion over use of proceeds.
Larimar Therapeutics is offering $75.0 million of common stock and associated pre‑funded warrants. The prospectus supplement outlines an at‑the‑market shelf background and an underwritten offering that includes a 30‑day option for up to an additional $11.25 million of common stock.
The company reports unaudited preliminary cash, cash equivalents and marketable securities of $136.9 million as of December 31, 2025. The filing notes FDA Breakthrough Therapy Designation for nomlabofusp and a planned BLA submission targeted for June 2026. The prospectus discloses 80,590,392 shares outstanding as the base for post‑offering calculations and describes usual issuance, dilution, lock‑up and underwriting terms.
Larimar Therapeutics announced that the FDA has granted Breakthrough Therapy Designation to nomlabofusp for treating adults and children with Friedreich’s ataxia, recognizing preliminary data that suggest substantial improvement over existing therapy. Following a START pilot program meeting, the FDA signaled continued alignment on using skin frataxin (FXN) as a novel surrogate endpoint to support a Biologics License Application seeking accelerated approval.
The company expects topline data from its ongoing open-label study in Q2 2026, plans to submit the BLA in June 2026, and is targeting a potential U.S. launch in the first half of 2027, if approved. A global confirmatory Phase 3 study is planned to start screening in Q2 2026, with Upright Stability Score as the primary endpoint. Larimar estimates it had $136.9 million in cash and investments as of December 31, 2025, with a projected runway into Q4 2026.